#LCSM Chat Topic 3/26: The Landscape of the #LungCancer World After Opdivo–Where We Are, Where We’re Going
Post by #LCSM Moderator Dr. H. Jack West: Earlier this month, the FDA made quick work of the application that Bristol-Myers-Squibb had just completed for Opdivo (nivolumab) for patients with squamous cell NSCLC that has previously been treated with standard chemotherapy. This was a very rapid decision, which highlighted the improvement in median overall survival from 6 to 9.2 months. So where are we now? What are the implications of the approval, both in terms of future approvals and the current treatment options for patients? Will Opdivo be the default best treatment… Read More
#LCSM Chat Topic 1/29 8PM ET: How Do Patients Decide Where to Seek Cancer Treatment?
Cancer is both a terrible, terrifying disease and big business. With costs of care rising and delivery of medicine changing, independent private practice groups are increasingly uncommon and sole practitioners are rare. Cancer care is now becoming consolidated as a system of larger institutions and networks, whether academic or private. And they build business with marketing and a keen eye on competition. These institutions are targeting market niches with major campaigns. Smaller, local centers may focus on the opportunity to get cancer care close to home. Other centers feature cutting edge care… Read More
You must be logged in to post a comment.